L-carnosine

DRUG4 trials

Sponsors

University of Pittsburgh, Abraham Reichenberg, Cairo University, University of Louisville

Conditions

Air Pollution ToxicityBipolar I DisorderCancerPeripheral NeuropathySchizophrenia

Phase 1

L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients

CompletedNCT02808624

Cairo UniversityCancer, Peripheral Neuropathy

Start: 2015-06-30End: 2016-12-31Updated: 2017-04-24

Phase 2

Carnosine and Cognitive Training in Schizophrenia

CompletedNCT02686697

Abraham ReichenbergSchizophrenia

Start: 2015-12-01End: 2022-07-19Updated: 2022-08-23

Unknown Phase

L-Carnosine for Bipolar I Disorder

CompletedNCT00177463

University of PittsburghBipolar I Disorder

Start: 2004-09-30End: 2007-12-31Updated: 2016-01-11

Nucleophilic Defense Against PM Toxicity (NEAT Trial)

CompletedNCT03314987

University of LouisvilleAir Pollution Toxicity

Start: 2018-04-01End: 2022-11-01Updated: 2026-01-06

Related Papers

Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial.

2025-02-064 citations

Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial.

2024-08-315 citations

Abstract 15872: Association Between Cognition and Cardiovascular Function is Modified by Carnosine and Carnosine-Acrolein Conjugates

Circulation2022-11-08

Abstract 336: Comparing Of <i>In-vivo</i> Carnosine Levels In Blood, Urine, And Muscle

Arteriosclerosis Thrombosis and Vascular Biology2022-05-01

Protocol to assess the efficacy of carnosine supplementation in mitigating the adverse cardiovascular responses to particulate matter (PM) exposure: the Nucleophilic Defense Against PM Toxicity (NEAT) trial

BMJ Open2020-12-013 citations